OakChart

Mentari Therapeutics Inc

MTRIHealthcare·Drug Manufacturers - Specialty & Generic·USA·Nano·NASD·Nov 11 • 3:58 PM ET

15.61+3.41 (27.94%)
2026-11-12 04:07 CET
Market cap
8.58 USD m
Revenue, TTM
0.82 USD m
Net income, TTM
-13.60 USD m
Free cash flow, TTM
-8.16 USD m
EPS diluted, TTM
-31.06
P/E
-
Compare

Price

MTRI against its 20, 50 and 200-day averages
2050200earnings
10.0015.0020.004.7M9.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MTRIclose 15.6120-day 14.9050-day 14.02200-day 12.2015.6152w high52w low

33.0% under the 52-week high of 23.30 on 22 Jul 2026. 52-week low 5.75 on 31 Mar 2026. Last 15 sessions, 50.0% high to low

Volume 6.56× normal · the line is the 50-bar volume average

Profile

MTRI
52-week range, 56% of the way up
5.7523.30

Mentari Therapeutics, Inc. is a biotechnology company, which engages in developing therapies for migraine prevention. Its portfolio includes MT-001 and MT-002. The company was founded on June 13, 2025 and is headquartered in Waltham, MA.

Employees6
IPONov 17, 2008
Beta1.02
ATR, 14d2.03
Rel volume6.56
Inst own37.37%

Snapshot

6 groups

Valuation

Index-
Market Cap8.57M
Enterprise Value7.44M
Income-13.60M
Sales0.82M
Book/sh-2.18
Cash/sh2.06
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees6
IPONov 17, 2008

Ratios

P/E-
Forward P/E-
PEG-
P/S10.45
P/B-
P/C7.59
P/FCF-
EV/EBITDA-
EV/Sales9.08
Quick Ratio0.50
Current Ratio0.50
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-31.06
EPS next Y-2.11
EPS next Q-0.41
EPS this Y30.70%
EPS next Y21.12%
EPS next 5Y17.21%
EPS past 3/5Y63.64% 66.67%
Sales past 3/5Y- -
EPS Y/Y TTM55.05%
Sales Y/Y TTM-82.91%
EPS Q/Q2.41%
Sales Q/Q-100.00%
EarningsNov 03 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own-
Insider Trans-
Inst Own37.37%
Inst Trans-
ROA-158.97%
ROE-224.38%
ROIC-
Gross Margin-71.90%
Oper. Margin-1238.62%
Profit Margin-1657.72%
SMA204.73%
SMA5011.33%
SMA20027.94%
Trades-

Technical

Shs Outstand0.55M
Shs Float-
Short Float-
Short Ratio0.69
Short Interest0.01M
52W High23.30 -33.01%
52W Low5.75 171.46%
Volatility27.90% 12.45%
ATR (14)2.03
RSI (14)52.94
Beta1.02
Rel Volume6.56
Avg Volume9.18K
Volume60,166

Performance

Perf Week-10.81%
Perf Month17.36%
Perf Quarter9.15%
Perf Half Y146.20%
Perf YTD47.25%
Perf Year-10.29%
Perf 3Y-79.94%
Perf 5Y-99.77%
Perf 10Y-99.93%
Recom1.00
Target Price34.00
Prev Close12.20
Price15.61
Change %27.94%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Nov 10, 2026InitiatedSStifelBuy$30+92.2%
Nov 10, 2026InitiatedJJefferiesBuy$30+92.2%

Peers

Mkt cap
TickerCompanyMkt cap
IXHLIncannex Healthcare Inc24.77M
CRDLCardiol Therapeutics Inc121.87M
OPTHOptimi Health Corp13.75M
SUPNSupernus Inc6.12B
ARTLArtelo Biosciences Inc1.20M
BIVIBioVie Inc13.51M
AXSMAxsome Therapeutics Inc7.85B
AVXLAnavex Life Sciences Corp98.26M
TNXPTonix Pharmaceuticals Holding Corp75.20M
EYPTEyePoint Inc30.74M

Insider trading

latest 14 of 33
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
ADAR1 Capital Management, LLC10% OwnerNov 05 '26Buy13.102,64034,57298,297Nov 09 08:18 PM
ADAR1 Capital Management, LLC10% OwnerOct 23 '26Buy1.3245956,584Oct 27 02:13 PM
ADAR1 Capital Management, LLC10% OwnerOct 19 '26Buy1.321,0861,434956,580Oct 20 05:31 PM
ADAR1 Capital Management, LLC10% OwnerOct 16 '26Buy1.3211955,494Oct 20 05:31 PM
ADAR1 Capital Management, LLC10% OwnerOct 14 '26Buy1.338,02110,668954,509Oct 15 04:39 PM
ADAR1 Capital Management, LLC10% OwnerOct 15 '26Buy1.329841,301955,493Oct 15 04:39 PM
ADAR1 Capital Management, LLC10% OwnerOct 13 '26Buy1.33564750946,488Oct 15 04:39 PM
ADAR1 Capital Management, LLC10% OwnerOct 06 '26Buy1.335,6017,436940,622Oct 08 06:27 PM
ADAR1 Capital Management, LLC10% OwnerOct 07 '26Buy1.333,0464,051943,668Oct 08 06:27 PM
ADAR1 Capital Management, LLC10% OwnerOct 08 '26Buy1.332,2562,997945,924Oct 08 06:27 PM
ADAR1 Capital Management, LLC10% OwnerOct 05 '26Buy1.3318,18224,182935,021Oct 05 05:11 PM
ADAR1 Capital Management, LLC10% OwnerOct 01 '26Buy1.3316,43121,850908,532Oct 05 05:11 PM
ADAR1 Capital Management, LLC10% OwnerOct 02 '26Buy1.338,30711,048916,839Oct 05 05:11 PM
ADAR1 Capital Management, LLC10% OwnerSep 15 '26Buy1.3054,25670,446883,761Sep 16 06:58 PM

News

latest 14 of 100

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2027Q12026-11-03-0.480--1.26--
2025Q32025-05-13-19.400--19.3521.26--
2025Q22025-02-12-36.400--36.4451.11--
2025Q12024-11-15-27.100--27.0561.26--
2024Q42024-09-3024.000--4.3451.29--
2024Q32024-05-14-36.000--3.5841.171.49-
2024Q22024-02-13-38.000--3.7081.241.13-
2024Q12023-11-15-152--15.2440.901.39-
2023Q22023-02-17-182--18.2660.47--
2023Q12022-11-11-812--81.1030.32--
2022Q42022-09-23-2,806-1,100-6,0480.520.751
2022Q32022-05-13-1,250-1,250-122.80.310.311
2022Q22022-02-15-1,550-1,175-154.650.270.132
2022Q12021-11-10-1,250-1,750-123.330.300.301
2021Q42021-09-24-2,050-1,355-202.390.000.001
2021Q32021-05-13-2,050-944.44-205.420.000.00-

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-9,946-7,376-964.360.000.00
2020FY-8,602-9,362-856.19-0.00
2021FY-7,600-6,744-759.180.000.00
2022FY-6,634-4,881-16,5831.091.77
2023FY-650--64.9194.144.13
2024FY-202--20.1434.60-
2026FY-3.003--3.8900.00-
2027FY--2.675--0.00
2028FY--2.110--0.00
2029FY--2.190--0.00
2030FY--2.700--4.90
2031FY--2.575--88.65

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027Q2S2026-11-101000.000.000.00
2027Q2R2026-11-10200-0.36-0.36-0.35
2027Q2R2026-11-09100-0.36-0.36-0.36
2027Q2E2026-11-10300-0.41-0.51-0.35
2027Q2E2026-11-09200-0.44-0.51-0.36
2027FYS2026-11-102000.000.000.00
2027FYS2026-11-061000.000.000.00
2027FYR2026-11-10100-3.05-3.05-3.05
2027FYE2026-11-10400-2.68-3.82-1.58
2027FYE2026-11-09300-2.55-3.82-1.58
2027FYE2026-11-06100-1.58-1.58-1.58
2025FYS2024-05-241006.776.776.77
2025FYS2024-05-231006.776.776.77
2025FYS2024-05-221006.776.776.77

Estimate history

EPS, annual-779.272-964.355-856.185-759.18-16582.7-64.919-20.143-83.637-31.205-31.0572
Period201820192020202120222023202420252026TTM
EPS, quarterly-27.056-36.445-19.352-8.932-4.367-5.129-7.328-14.339-4.262
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
Sales, annual00001.0894.1364.598000.82
Period201820192020202120222023202420252026TTM
Sales, quarterly1.2651.1121.2621.3051.120.82000
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
Shares, annual0.010.010.010.0160.0010.1660.4460.20.5340.549
Period201820192020202120222023202420252026MRQ
Shares, quarterly0.0670.0720.1210.20.260.280.3310.5340.549
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.820.000.004.604.141.090.000.000.00
Cost of Goods Sold Incl. D&A1.410.710.534.103.001.020.200.180.09
Gross Profit-0.59-0.71-0.530.501.140.07-0.20-0.18-0.09
Selling, General and Administrative Excl. Other9.579.197.918.639.2113.869.748.9710.30
Research and Development2.673.032.823.773.737.285.345.814.35
Other Operating Expense0.000.000.000.000.310.000.000.000.00
Operating Income-10.16-9.90-8.45-8.13-8.38-13.79-9.94-9.15-10.39
Interest Expense0.010.010.370.000.000.000.360.000.00
Unusual Expense1.651.650.000.000.004.79-0.240.00-
Net Income Before Taxes-11.66-11.37-8.69-7.67-7.93-18.60-10.20-8.94-10.01
Income Taxes0.000.000.000.010.010.000.000.000.00
Consolidated Net Income-11.66-11.37-8.69-7.68-7.95-18.60-10.20-8.94-10.01
Net Income From Continuing Operations-11.66-11.37-8.69-7.68-7.95-18.60-10.20-8.94-10.01
Net Income-13.60-12.99-8.16-7.68-7.95-18.60-10.20-8.94-10.01
EPS (Recurring)-22.75-28.44-83.64-20.14-64.92-13,595.31-771.81-856.12-964.37
EPS (Basic, Before Extraordinaries)-31.06-31.20-83.64-20.14-64.92-16,582.70-759.18-856.18-964.36
EPS (Diluted)-31.06-31.20-83.64-20.14-64.92-16,582.70-759.18-856.18-964.36
EBITDA-9.39-9.19-7.91-7.53-7.81-13.32-9.74-8.97-10.30
Non-Operating Income (Expense)0.160.180.130.470.44-0.02-0.150.210.38
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.100.110.120.110.220.700.610.993.08
Price To Sales Ratio9.07-0.640.440.550.24---
Gross Margin-71.90--10.8027.586.27---
Operating Margin-1,238.62---176.92-202.60-1,265.95---
Net Margin-1,657.72---166.94-192.18-1,707.32---
Shares Outstanding0.550.530.200.450.170.000.020.010.01
Market Capitalization8.588.586.5116.8530.843.06256.01322.51444.28

Income statement, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q42025Q32025Q2
Total Revenue0.000.000.000.821.121.301.261.11
Cost of Goods Sold Incl. D&A0.220.260.130.790.870.861.220.78
Gross Profit-0.22-0.26-0.130.030.250.450.050.33
Selling, General and Administrative Excl. Other1.792.952.682.152.012.292.162.54
Research and Development0.210.811.020.630.580.110.911.06
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.01-3.21-2.82-2.12-1.76-1.84-2.12-2.21
Interest Expense0.000.010.000.000.000.02-0.35
Unusual Expense0.001.650.000.000.000.000.000.00
Net Income Before Taxes-2.00-4.84-2.79-2.03-1.73-1.79-2.12-2.58
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.00-4.84-2.79-2.03-1.73-1.79-2.12-2.58
Net Income From Continuing Operations-2.00-4.84-2.79-2.03-1.73-1.79-2.12-2.58
Net Income-2.33-6.27-2.97-2.03-1.73-1.79-2.12-2.58
EPS (Recurring)-4.26-11.70-7.33-5.13-4.37-8.93-19.35-36.45
EPS (Basic, Before Extraordinaries)-4.26-14.34-7.33-5.13-4.37-8.93-19.35-36.45
EPS (Diluted)-4.26-14.34-7.33-5.13-4.37-8.93-19.35-36.45
EBITDA-1.79-2.95-2.68-1.96-1.61-1.71-1.99-2.08
Non-Operating Income (Expense)0.020.030.020.090.040.07-0.01-0.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.020.020.040.030.020.030.040.02
Price To Sales Ratio9.073.490.800.931.801.320.460.69
Gross Margin---3.1922.0034.153.6529.68
Operating Margin----258.57-157.45-141.19-167.67-198.46
Net Margin----247.29-154.17-137.07-168.12-231.63
Shares Outstanding0.550.530.330.280.260.200.120.07
Market Capitalization8.588.282.142.975.706.512.503.43

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments2.2310.796.618.966.227.415.8513.8020.13
Short Term Receivables0.000.000.350.260.090.010.050.070.04
Inventories0.000.001.241.622.490.000.000.000.00
Other Current Assets0.442.080.480.500.800.960.420.320.15
Total Current Assets2.6812.878.6911.339.608.386.3114.1920.32
Net Property, Plant & Equipment0.220.991.250.720.900.330.400.040.04
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.001.621.781.952.111.061.090.910.97
Other Assets0.130.100.100.100.180.010.000.000.00
Total Assets3.0315.5811.8214.1112.799.787.8015.1421.33
Short Term Debt Incl. Current Port. of LT Debt0.000.440.320.380.400.080.070.000.00
Accounts Payable0.930.280.630.541.170.000.000.000.00
Other Current Liabilities1.031.131.031.081.752.131.611.200.71
Total Current Liabilities1.961.841.972.003.322.221.681.200.71
Long Term Debt0.000.310.640.020.390.190.250.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities1.962.152.622.023.712.401.921.200.71
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1.0813.439.2112.099.087.385.8813.9520.62
Total Shareholders Equity1.0813.439.2112.099.087.385.8813.9520.62
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1.0813.439.2112.099.087.385.8813.9520.62
Total Liabilities & Stockholders Equity3.0315.5811.8214.1112.799.787.8015.1421.33
Book Value Per Share2.0167.1020.6472.656,976.33458.13562.981,335.791,991.44
Tangible Book Value Per Share2.0159.0116.6560.955,355.75392.19458.911,248.961,897.93
Full-Time Employees6131313--13129
Price to Book Ratio-7.150.481.522.550.3434.7157.6327.3777.07
Return on Assets-122.23-63.43-59.20-59.10-164.83-117.94-77.91-54.91-48.34
Return on Equity-156.77-76.77-72.08-75.09-226.07-157.30-90.18-57.94-50.14
Return on Invested Capital-1,168.44-59.40-77.92-65.65-196.45-134.86-145.91-71.80-32.53
Quick Ratio1.376.993.784.862.143.783.7711.8728.51
Current Ratio1.376.994.415.662.893.783.7711.8728.51

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-13.14-12.56-8.16-7.68-7.95-18.60-10.20-8.94-10.01
Depreciation0.770.710.530.600.600.510.120.110.09
Other Funds (Non Cash)3.343.290.010.450.635.580.841.173.01
Funds from Operations-9.03-8.57-7.62-6.62-7.14-12.85-9.34-7.73-6.91
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.87-0.08-0.48-0.37-0.14-2.73-0.450.360.28
Cash from Operating Activities-8.16-8.64-8.10-6.99-7.28-15.58-9.79-7.37-6.62
Capital Expenditures0.000.000.00-0.01-0.16-0.04-0.00-0.04-0.03
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.090.000.000.00
Purchase or Sale of Investments0.000.000.000.000.00-0.430.003.83-2.06
Purchase of Investments-0.02-0.04-0.04-0.04-0.04-0.430.00-0.04-2.06
Sale Or Maturity of Investments0.020.040.040.040.040.000.003.880.00
Other Uses0.000.000.000.00-0.50-0.300.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.01-0.66-0.67-0.003.79-2.09
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.270.0912.274.6510.6815.3610.85-0.030.21
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.270.0912.274.6510.6815.3610.85-0.030.21
Proceedsfrom Stock Options0.270.097.254.6510.6815.3610.85-0.030.00
Issuance or Reduction of Debt, Net0.000.000.000.000.00-0.290.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities0.270.0912.274.6510.6815.0710.85-0.030.21
Exchange Rate Effect-----0.000.49-0.42-
Net Change in Cash-7.89-8.554.17-2.342.74-1.191.56-4.03-8.51
Free Cash Flow-8.16-8.64-8.10-7.00-7.44-15.62-9.79-7.42-6.65
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q4
Cash & Short Term Investments1.132.235.207.009.3711.12
Short Term Receivables0.000.000.000.180.340.47
Inventories0.000.000.000.950.890.96
Other Current Assets0.130.441.690.660.190.32
Total Current Assets1.262.686.898.7910.8012.87
Net Property, Plant & Equipment0.000.220.640.760.880.99
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets-0.001.501.541.581.62
Other Assets0.040.130.100.100.100.10
Total Assets1.313.039.1311.1913.3615.58
Short Term Debt Incl. Current Port. of LT Debt0.000.000.390.410.420.44
Accounts Payable1.670.930.230.170.370.37
Other Current Liabilities0.831.031.600.910.761.03
Total Current Liabilities2.511.962.211.481.551.84
Long Term Debt0.000.000.030.120.220.31
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.511.962.241.601.772.15
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-1.201.086.899.5911.5913.43
Total Shareholders Equity-1.201.086.899.5911.5913.43
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-1.201.086.899.5911.5913.43
Total Liabilities & Stockholders Equity1.313.039.1311.1913.3615.58
Book Value Per Share-2.182.0120.8034.1944.5167.10
Tangible Book Value Per Share-2.182.0116.2728.7038.4459.01
Full-Time Employees-6---13
Price to Book Ratio-7.157.700.310.310.490.48
Return on Assets-158.97-122.41-90.53-77.84-68.93-59.57
Return on Equity-224.38-157.00-119.82-97.20-82.17-72.10
Return on Invested Capital--543.20-42.85-20.88-14.63-13.02
Quick Ratio0.501.373.115.306.376.47
Current Ratio0.501.373.115.946.956.99

Cash flow, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q4
Net Income-2.33-5.77-3.04-2.01-1.73-2.01
Depreciation0.220.260.140.160.160.15
Other Funds (Non Cash)0.093.17-0.000.100.020.06
Funds from Operations-2.02-2.35-2.90-1.75-1.55-1.80
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.88-0.561.14-0.60-0.06-0.19
Cash from Operating Activities-1.14-2.91-1.76-2.35-1.61-1.99
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.00-0.02-0.00-0.02-0.00
Sale Or Maturity of Investments0.00-0.000.020.000.020.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00-0.000.000.000.00
Change in Capital Stock0.04-0.000.230.00-0.148.37
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.04-0.000.230.00-0.148.37
Proceedsfrom Stock Options0.04-0.000.230.00-0.143.31
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.04-0.000.230.00-0.148.37
Net Change in Cash-1.10-2.91-1.53-2.35-1.746.38
Free Cash Flow-1.14-2.91-1.76-2.35-1.61-1.99

Revenue breakdown

Pharmaceutical Preparations2025: 4.94M
Canada2025: 4.94M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.0M-7.00K
2026-10-150.14%0.0M0.5M90.10K
2026-09-300.84%0.0M0.4M91.62K
2026-09-150.39%0.0M0.4M92.22K
2026-08-311.25%0.0M0.2M91.76K
2026-08-142.94%0.0M0.2M250.50K
2026-07-313.34%0.0M0.2M249.79K
2026-07-154.79%0.0M0.2M165.59K
2026-06-305.65%0.0M0.3M163.00K
2026-06-155.68%0.0M0.3M165.11K
2026-05-294.05%0.0M0.3M168.29K
2026-05-150.80%0.0M0.3M9.63K
2026-04-301.07%0.0M0.3M10.47K
2026-04-152.89%0.0M0.3M11.38K
2026-03-313.16%0.0M0.3M12.05K
2026-03-132.29%0.0M0.3M9.47K
2026-02-273.14%0.0M0.3M9.51K
2026-02-134.11%0.0M0.3M35.48K
2026-01-305.90%0.0M0.3M35.58K
2026-01-1510.15%0.0M0.1M34.78K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-06SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-058-KCurrent report2026-11-04SEC
2026-11-058-KCurrent report2026-11-04SEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-11-02425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-28424B3SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-27425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01EFFECTEffectiveness filing by commission orderSEC
2026-09-29S-4/ASEC
2026-09-188-KCurrent report2026-09-16SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-09425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-09-0910-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-09S-4/ASEC
2026-08-14SCHEDULE 13GSEC
2026-07-22425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-22425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-228-KCurrent report2026-07-22SEC
2026-07-20425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-14SEC
2026-07-10425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1134.57K100
2026-1085.72K1200
2026-09118.08K300
2026-080000
2026-0742.63K600
2026-06219.39K700
2026-05894.64K400
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
-

Funds

Fund% owned
-

OakChart. MTRI. Cached 15 minutes.